反义显像技术的研究进展

夏劲松

反义显像技术的研究进展

夏劲松

文章导航 > 国际放射医学核医学杂志 > 2001, 25 > 2: (62-65)

引用本文:

Citation:

反义显像技术的研究进展

夏劲松

430030 湖北武汉, 华中科技大学同济医学院附属同济医院核医学科

作者简介: 夏劲松(1973-),男,湖北通山人,华中科技大学同济医学院博士研究生。主要研究方向:特异性靶向药物的研制和肿瘤核医学。;

中图分类号: R817.4

Progression of antisense oligonucleotides for non-invasive imaging in vivo

XIA Jin-song

Department of Nuclear Medicine, Tongji Hospital, Tongji Medical University, Hubei Wuhan 430030, China
CLC number: R817.4

摘要: 反义显像是利用放射性核素标记的反义寡核苷酸,通过体内核酸杂交而显示目的基因表达的一种显像方法,具有设计简便、合成简易、安全性高、免疫原性低等特点。成功的反义显像要求反义寡核苷酸易被细胞摄取、耐核酸酶、杂交稳定、标记简单。脂质体、受体等介导的反义RNA转移,反义寡核苷酸的化学修饰以及标记方法的改进将大大加快反义显像的临床应用。
- 反义显像 /
- 受体 /
- 脂质体 /
- 反义寡核苷酸
Abstract: Antisense imaging is widely used as a novel method to assess gene expression by nucleic acid hybridization with anisense oligonucleotide labelled by radionucide in vivo, with advantages of easy controlling for synthesis, high reliability and low immunogenicity. The requirements for ideal antisense imaging include easy intakeing by cells, convenient labelling, stable hybridization and the tolerance against nuclease. The progression in antisense imaging, such as the transfer of antisense RN A mediated by liposomes or receptor, chemical modification of antisense oligonucleotide and the improvement of labelling, will greatly improve the clinical application of antisense imaging.
- antisense imaging /
- receptor /
- liposomes /
- antisense oligonucleotide
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Myers KJ,Dean NM.Sensible use of antisense:how to use oligonucleotides as research tools[J].Trends Phimacol Sci,2000,21:19-23.
[2]	Poston RS,Tran KP,Mann M J,et al.Prevention of ischemically induced neointimal hyperplasia using ex vivo antisense oligodeoxynucleotide[J].J Heart Lung Transplant,1998,17:349-355.
[3]	Hnatowich DJ.Changing focus:applying antisense to nuclear medicine imaging[J].Mol Med Today,1999,5:151.
[4]	ManiS,Gu Y,Wadler S,et al.Antisense therapeutics in oncology:points to consider in their clinical evaluation[J].Antisense Nucleic Acid Drug Dev,1999,9:543-547.
[5]	Asaoka K,Tadam,Sawamura Y,et al.Dependence of efficient adenviral gene delivery in malignant glioma cells on the expression levels of the coxsackievirus and adenovirus recepter[J].J Neursurg,2000,92:1002-1008.
[6]	Malatynska E,Matheson GK,Goldenberg R,et al.Effects of treatment with GABA(A) receptor subunit antisense oligodeoxynucleotides on GABA-stimulated 36C1-infiux in the rat cerebral cortex[J].Neurochem Int,2000,36:45-54.
[7]	Cooper SR,Taylor JK,Miraglia LJ,et al.Pharmacology of antisense oligonucleotide inhiibitors of protein expression[J].Pharmacol Ther,1999,82.427-435.
[8]	Hogrefe RI.An antisense oligonucleotide primer[J].Antisense Nucleic Acid Drug Dev,1999,9:351-357.
[9]	Gauchez AS,Du Moulinet D'Hardemare A,Lunardi J,et al.Potential use of radiolabeled antisense oligonucleotides in oncology[J].Anticancer Res,1999,19:4989-4997.
[10]	Alt M,Eisenhardt S,Serwe M,et al.Comparative inhibitory potential of diffently modified antisense oligodeoxynucleotides on hepatitis C virus translation[J].Eur J Clin Invest.1999,29:868-876.
[11]	Hnatowich DJ.Antisense and nuclear medicine[J].J Nucl Med,1999,40(4):693-703.
[12]	Tavitian B.In vivo antisense imaging[J].Q J Nucl Med,2000,44:236-255.
[13]	Dewanjee MK,Vargas R,Ghafouripour AK,et al.Kinetics of intracellular hybridization of c-myc mRNA oncogene with ¹¹¹In labeled antisense deoxyoligonucleotide probes in leukemic cells[J].J Nucl Med,1994,34:224.
[14]	Lu Xiao-ming,Alan J,Fischman,et al.Antisense DNA delivery in vivo:Liver targeting by receptor-mediated uptake[J].J Nucl Med,1994,35:269-275.
[15]	Dewanjee M K,Ghafouripour AK,Kapadvanjwala M,et al.Radiolabeled antisense oligodeoxynucleotides:in vitro and in vivo applications[J].JClin Immunoassay,1993,16:276-289.
[16]	HnatowichDJ,Winnard P,Virzi F,et al.Technetium-99m labeling of DN A oligonucleotides[J].J Nud Mecl,1995,36:2306-2314.
[17]	Hnatowich DJ.Antisense imaging:Where are we now?[J].Cancer Biother Radiopharm,2000,15:447-457.

[1]	郑建国 , 谭天秩 . 放射性核素反义治疗在恶性肿瘤中的应用. 国际放射医学核医学杂志, 1998, 22(6): 242-244.
[2]	张春 . 受体介导的反义治疗研究. 国际放射医学核医学杂志, 2000, 24(3): 104-106.
[3]	杨卫东 , 朱承谟 . 肿瘤反义显像技术中的若干问题. 国际放射医学核医学杂志, 1998, 22(6): 244-247.
[4]	袁杰 , 刘兴党 , 韩梅 . SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用. 国际放射医学核医学杂志, 2013, 37(1): 30-33, 41. doi: 10.3760/cma.j.issn.1673-4114.2013.01.009
[5]	赵利军 , 刘彦仿 , 周前 . 反义显像技术在肿瘤诊断中的应用. 国际放射医学核医学杂志, 1996, 20(3): 121-123.
[6]	秦光明 . 肿瘤核素反义显像技术的研究现状与展望. 国际放射医学核医学杂志, 2001, 25(5): 213-216.
[7]	柳江燕 , 陈雪红 . 肿瘤受体显像及介导靶向治疗的研究进展. 国际放射医学核医学杂志, 2005, 29(6): 258-260.
[8]	鲍伟奇 , 邱春 , 管一晖 . γ-氨基丁酸A型-苯二氮受体显像剂在神经系统疾病中的应用. 国际放射医学核医学杂志, 2012, 36(1): 1-8. doi: 10.3760/cma.j.issn.1673-4114.2012.01.001
[9]	侯敏 . 癫痫的PET受体显像. 国际放射医学核医学杂志, 2003, 27(4): 168-171.
[10]	李辉 , 孙俊杰 , 李卫鹏 , 訾刚 , 袁超 . ⁹⁹Tc^m-MIBI脂质体的制备及特征分析. 国际放射医学核医学杂志, 2018, 42(5): 425-429. doi: 10.3760/cma.j.issn.1673-4114.2018.05.007

点击查看大图

计量

文章访问数: 1083
HTML全文浏览量: 115
PDF下载量: 2

反义显像技术的研究进展

夏劲松

作者简介:夏劲松(1973-),男,湖北通山人,华中科技大学同济医学院博士研究生。主要研究方向:特异性靶向药物的研制和肿瘤核医学。

430030 湖北武汉, 华中科技大学同济医学院附属同济医院核医学科

收稿日期: 2000-06-29

关键词:

摘要: 反义显像是利用放射性核素标记的反义寡核苷酸,通过体内核酸杂交而显示目的基因表达的一种显像方法,具有设计简便、合成简易、安全性高、免疫原性低等特点。成功的反义显像要求反义寡核苷酸易被细胞摄取、耐核酸酶、杂交稳定、标记简单。脂质体、受体等介导的反义RNA转移,反义寡核苷酸的化学修饰以及标记方法的改进将大大加快反义显像的临床应用。